- ホーム
- > 洋書
- > ドイツ書
- > Mathematics, Sciences & Technology
- > Medicine & Pharmacy
- > pharmacy, pharmacology, toxicology
Full Description
This is a timely and essential companion to the recently published Antimicrobial Resistance in the 21st Century, Second Edition. Antimicrobial resistance is a major threat to global population health, with government reports projecting it could result in over 10 million deaths in the next 35 years. Development of new agents to combat this threat is one of the WHO's top priorities, but in 2017, it conceded that the current drug development pipeline was insufficient to mitigate the threat. This book discusses recent progress and bolster new agent discovery and development, by providing researchers and students who will soon enter the field with a thorough guide to the advancements made in the last decade.
Coverage includes new systemic antimicrobials approved since 2010, with detailed analysis of antibiotics, antivirals, antifungals, and antiparasitics, as well as agents in development for future use. Discussion of each drug will include its chemical nature, pharmacology/pharmacokinetics, antimicrobial spectrum, dosage, adverse reactions, drug interactions, microbial resistance, indications, clinical efficacy compared to older agents, and lists of similar agents with cost comparison. This volume is designed for researchers and students of infectious disease and medical microbiology, as well as clinicians in need of a comprehensive guide to newly developed agents.
Contents
1. Antimicrobial Resistance: A crisis in the making.- 2: New Cephalosporins: 5th and 6th generations.- 3: New β-lactam-β-lactamase inhibitor combinations.- 4: New Glycopeptides: Televancin, dalbavancin and oritavancin.- 5: A new fluoroquinolone—Delafloxacin.- 6: New Oxazolininone---Tedizolid.- 7: New Tetracyclines: Eravacycline and Omadacycline.- 8: Pleuromutilin: A new class of antibiotic: Lefamulin.- 9: New anti-tuberculous drugs: Bedaquiline, Delamanid and Pretomanid.- 10: New systemic antifungal: Isavuconazole.- 11: Newly approved anti-parasitic drugs for malaria, fascioliasis, onchocerciasis, Chagas disease and African trypanosomiasis.- 12:New antiretroviral agents for HIV infection.- 13: New Antiviral agents for cytomegalovirus diseases.- 14: New antiviral agent for influenza: Baloxavir.- 15: Direct antiviral agents for hepatitis C.- 16: Antiviral drugs for SARS-CoV-2 and COVID-19.- 17: New promising antimicrobials in development and novel approaches for treatment of infections.-
